Skip to content

Investors & Media


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Learn More

Creating value by saving sight through transformative science.

Press Releases

12-May-21

Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate

12-May-21

Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD

GB-102 1mg has shown competitive durability and anatomical control versus aflibercept Trend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patients Developing enhanced formulations and seeking partner funding for additional clinical trials of GB-102 Focus on

05-May-21

Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO Trial

REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced it will host a conference call and

View All News
Events
View All Events

SEC Filings

View All SEC Filings

Connect with Us
Sign up for ongoing news and events.
Font Resize